Form 4: Replimune Group Director Acquires Stock Options
SEC Form 4 Filing
Director Hyam Levitsky acquired 32,000 stock options in Replimune Group, Inc. on April 1, 2024, according to a recent SEC filing.
Summary
- On April 1, 2024, Hyam Levitsky, a director of Replimune Group, Inc., acquired 32,000 stock options.
- The exercise price of these options is $7.73.
- The options vest entirely on April 1, 2025.
- The options expire on April 1, 2034.
- Following the transaction, Levitsky directly owns 32,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction: Hyam Levitsky acquired stock options. |
| 04/01/2025 | Vesting date: The stock options vest entirely. |
| 04/01/2034 | Expiration date: The stock options expire. |
| 04/03/2024 | Date of filing: The Form 4 was signed on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.